Further antibody escape by Omicron BA.4 and BA.5 from vaccine and BA.1 serum
Tuekprakhon, A.; Huo, J.; Nutalai, R.; Dijokaite-Guraliuc, A.; Zhou, D.; Ginn, H. M.; Sekvaraj, M.; Liu, C.; Mentzer, A. J.; Supasa, P.; Duyvesteyn, H. M. E.; Das, R.; Skelly, D.; Ritter, T. G.; Amini, A.; Bibi, S.; Adele, S.; Johnson, S. A.; Constantinides, B.; Webster, H.; Temperton, N.; Klenerman, P.; Barnes, E.; Dunachie, S. J.; Crook, D.; Pollard, A. J.; Lambe, T.; Goulder, P.; OPTIC consortium, ; ISARIC4C consortium, ; Fry, E. E.; Mongkolsapaya, J.; Ren, J.; Stuart, D. I.; Screaton, G. R.
Show abstract
The Omicron lineage of SARS-CoV-2, first described in November 2021, spread rapidly to become globally dominant and has split into a number of sub-lineages. BA.1 dominated the initial wave but has been replaced by BA.2 in many countries. Recent sequencing from South Africas Gauteng region uncovered two new sub-lineages, BA.4 and BA.5 which are taking over locally, driving a new wave. BA.4 and BA.5 contain identical spike sequences and, although closely related to BA.2, contain further mutations in the receptor binding domain of spike. Here, we study the neutralization of BA.4/5 using a range of vaccine and naturally immune serum and panels of monoclonal antibodies. BA.4/5 shows reduced neutralization by serum from triple AstraZeneca or Pfizer vaccinated individuals compared to BA.1 and BA.2. Furthermore, using serum from BA.1 vaccine breakthrough infections there are likewise, significant reductions in the neutralization of BA.4/5, raising the possibility of repeat Omicron infections.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Structure selected RBM immunogens prime polyclonal memory responses that neutralize SARS-CoV-2 variants of concern 97%
- A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 delta variant 97%
- Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens 95%
Similar papers in this journal
- Nanobody repertoire generated against the spike protein of ancestral SARS-CoV-2 remains efficacious against the rapidly evolving virus 97%
- Functional characterization and lineage analysis of broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics 96%
- Nanobody Repertoires for Exposing Vulnerabilities of SARS-CoV-2 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.